Addiction最新文献

{"title":"Do not conflate debates on regulating therapeutic use of psychotropic substances with those on the legalization of their non-therapeutic use.","authors":"Daniele Zullino","doi":"10.1111/add.16667","DOIUrl":"https://doi.org/10.1111/add.16667","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142386493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Affective dynamics surrounding craving, non-heavy alcohol use and binge drinking in female patients with alcohol use disorder and controls: An experience sampling method study.","authors":"Nicolas Leenaerts, Thomas Vaessen, Stefan Sunaert, Jenny Ceccarini, Elske Vrieze","doi":"10.1111/add.16682","DOIUrl":"https://doi.org/10.1111/add.16682","url":null,"abstract":"<p><strong>Background and aims: </strong>Studies show that higher levels of positive affect (PA) and lower levels of negative affect (NA) are related to craving and alcohol consumption at a daily level in men, but little is known on these associations at a momentary level, and whether they are present in women. This study measured the dynamics of within-person NA and PA surrounding craving, non-heavy alcohol use and binge drinking in women with alcohol use disorder (AUD) and female controls without AUD.</p><p><strong>Methods: </strong>53 female patients with AUD and 75 female controls, all recruited in Belgium, were included in an experience sampling study where they reported on momentary NA, PA, craving and alcohol use in daily life over a period of 12 months. Assessments occurred eight times a day on Thursdays, Fridays and Saturdays in seven bursts of three weeks.</p><p><strong>Results: </strong>Within-person NA at a previous assessment (t<sub>-1</sub>) predicted craving at the current assessment (t<sub>0</sub>) in patients with AUD in a positive linear [β = 0.043; 95% confidence interval (CI) = 0.002, 0.057; P = 0.041] and quadratic fashion (β = 0.034; CI = 0.011, 0.057; P = 0.004). Within-person PA at t<sub>-1</sub> predicted craving at t<sub>0</sub> in patients with AUD with a positive quadratic relation (β = 0.042; CI = 0.08, 0.065; P < 0.001). Within-person NA at t<sub>-1</sub> negatively predicted non-heavy alcohol use at t<sub>0</sub> in a linear fashion in controls (β = -0.495; CI = -0.677, -0.312; P < 0.001) and patients with AUD (β = -0.276; CI = -0.421, -0.132; P < 0.001). Within-person PA at t<sub>-1</sub> significantly predicted non-heavy alcohol use at t<sub>0</sub> with a positive linear term (β = 0.470; CI = 0.329, 0.610; P < 0.001) in controls, but with a positive linear term (β = 0.399; CI = 0.260, 0.454; P < 0.001) and a positive quadratic term (β = 0.203; CI = 0.060, 0.347; P = 0.003) in patients with AUD. Within-person NA at t<sub>-1</sub> predicted binge drinking at t<sub>0</sub> in patients with AUD with a significant quadratic term (β = 0.236; CI = 0.060, 0.412; P = 0.008), but not for controls. Within-person PA at t<sub>-1</sub> predicted binge drinking at t<sub>0</sub> in patients with AUD with a significant quadratic term (β = 0.378; CI = 0.215, 0.542; P < 0.001), and this was also the case for controls (β = 0.487; CI = 0.158, 0.770; P < 0.001). Non-heavy alcohol use at t<sub>0</sub> predicted lower levels of NA at t<sub>+1</sub> in both patients with AUD (β = -0.161; SE = 0.044; CI = -0.248, 0.074; P = 0.001) and controls (β = -0.114; CI = -0.198, -0.029; P = 0.010). Non-heavy alcohol use at t<sub>0</sub> also predicted higher levels of PA at t<sub>+1</sub> in both patients with AUD (β = 0.181; CI = 0.088, 0.274; P < 0.001) and controls (β = 0.189; CI = 0.101, 0.278; P < 0.001).</p><p><strong>Conclusions: </strong>The momentary relation between affect and craving or alcohol use seems to be non-linear in female patien","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public health considerations about tetrahydrocannabinol-infused beverages.","authors":"Cassidy R LoParco, Kayla K Tillett, Julia Chen-Sankey, Carla J Berg, Matthew E Rossheim","doi":"10.1111/add.16676","DOIUrl":"https://doi.org/10.1111/add.16676","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review.","authors":"Caroline Gregory, Krishan Yadav, Jordyn Linders, Lindsey Sikora, Debra Eagles","doi":"10.1111/add.16646","DOIUrl":"https://doi.org/10.1111/add.16646","url":null,"abstract":"<p><strong>Background and aims: </strong>Buprenorphine is an evidence-based treatment for opioid use disorder, and the risk of precipitated withdrawal contributes to its underuse. The goal of this systematic review was to determine the incidence of buprenorphine-precipitated withdrawal in adults with opioid use disorder.</p><p><strong>Methods: </strong>This systematic review was registered on PROSPERO (CRD42023437634). We searched Medline, Embase Classic + Embase, and Cochrane CENTRAL from inception to 10 November 2023, and included original research that reported the incidence of sublingual buprenorphine-precipitated withdrawal in adults with opioid use disorder. Primary screening was completed by four independent reviewers. Full text review, data extraction and risk of bias assessments using the Newcastle Ottawa Scale and the Cochrane Risk of Bias 2 tool were completed by two independent reviewers. The primary outcome was precipitated withdrawal. Secondary outcomes were baseline opioids used, induction dose, initial Clinical Opiate Withdrawal Scale (COWS) score, location of induction, definition and severity of precipitated withdrawal and adverse events. The range of incidence of precipitated withdrawal across studies was described.</p><p><strong>Results: </strong>Our search yielded 10 197 unique citations. Twenty-one cohort and five randomized trials met inclusion criteria (n = 4497, range 20-1293). The overall incidence of precipitated withdrawal ranged from 0 to 13.2%. Nine studies defined precipitated withdrawal; definitions were inconsistent. Most patients used heroin at baseline. The most common initial dose of buprenorphine was between 2 mg and 8 mg (range: 0.075 mg-24 mg). Initial minimum COWS score ranged from 5 to 13. Induction locations included home, inpatient, emergency department, pre-hospital, outpatient and residential units. Of the fifteen studies with cases of precipitated withdrawal, nine studies did not report the severity of withdrawal experienced. Other induction-related adverse events varied. The overall quality of included studies was poor.</p><p><strong>Conclusions: </strong>The best available evidence suggests the incidence of buprenorphine-precipitated withdrawal in adults with opioid use disorder is low and should not be a barrier to use.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of nicotine mouth spray on urges to vape: A randomized, placebo-controlled, pharmacodynamic clinical trial in exclusive e-cigarette users.","authors":"Tobias Danielsson, Hedvig Bennet, Bryan McColgan, Jianfeng Wang","doi":"10.1111/add.16669","DOIUrl":"10.1111/add.16669","url":null,"abstract":"<p><strong>Aims: </strong>To determine whether nicotine mouth spray provides rapid and prolonged relief of urges to vape and measure the steady-state plasma nicotine levels during vaping and ad libitum mouth spray usage in e-cigarette users.</p><p><strong>Design: </strong>Randomized, parallel group, double-blind trial.</p><p><strong>Setting: </strong>Single site at Hammersmith Medicines Research Ltd (HMR), London, UK.</p><p><strong>Participants: </strong>216 (25.9% females, average age 27.6 ± 7.63 [standard deviation, SD]) exclusive vapers who used their e-cigarette within 30 minutes of waking up and had vaped about 2 years on average.</p><p><strong>Interventions: </strong>Two sprays of 1 mg nicotine mouth spray (Nicorette QuickMist Freshmint, n = 109), or placebo (identical in appearance and presentation, n = 107).</p><p><strong>Measurements: </strong>Urge to vape was rated on a 100 mm visual analogue scale before and repeatedly for 2 hours after administration. The primary outcome measured average change from baseline in urges to vape ratings during the first hour.</p><p><strong>Findings: </strong>Nicotine mouth spray achieved statistically significantly greater reductions in urges to vape than placebo from the first assessment point at 30 seconds to 1 hour, when the estimated mean treatment difference was 11.90 mm (95% confidence interval [CI] = 6.86-16.95, P < 0.001). The integrated urge to vape over 11 hours ad libitum usage showed a statistically significant benefit compared with placebo (2.00 [0.88 SD] vs 2.51 [0.84 SD], P < 0.001). Mean steady-state plasma nicotine concentrations were lower after nicotine mouth spray usage compared with vaping (6.22 [4.70 SD] ng/ml vs 9.91 [7.59 SD] ng/ml, respectively). Adverse events were more commonly reported in the nicotine mouth spray group and were mostly mild.</p><p><strong>Conclusions: </strong>Among regular e-cigarette users, nicotine mouth spray provided statistically significant and fast relief of urges to vape one hour after dosing. Nicotine mouth spray showed statistically significant reductions in urges to vape as soon as 30 seconds and up to 2 hours after dosing compared with placebo, and nicotine mouth spray was well-tolerated and safe.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing the exponential growth of Mendelian randomization studies","authors":"Marcus R. Munafò,&nbsp;Jamie Brown,&nbsp;Marita Hefler,&nbsp;George Davey Smith","doi":"10.1111/add.16627","DOIUrl":"10.1111/add.16627","url":null,"abstract":"&lt;p&gt;Much of the research we publish relates to questions of cause and effect. In an ideal world, we would subject these questions to experimentation, randomizing study participants to different conditions. However, in many cases—particularly in the context of addiction—such randomization is simply not possible. We cannot randomize tobacco-naïve children to use e-cigarettes, for example, to determine whether or not vaping acts as a ‘gateway’ to subsequent smoking. In these cases, we have to rely on observational methods, and these suffer from well described problems of confounding, including reverse causality.&lt;/p&gt;&lt;p&gt;Several methods exist for strengthening causal inference in such cases, from the use of prospective data and statistical adjustment for confounding through to propensity score matching and the use of natural experiments. One method, in particular, has experienced exponential growth recently—Mendelian randomization (MR) [&lt;span&gt;1, 2&lt;/span&gt;]. This approach uses genetic variants as proxies for an exposure of interest, effectively as a form of instrumental variable analysis. If relevant assumptions hold, this should protect against confounding, including reverse causality, due to the random allocation of genotype at meiosis and the fact that environmental exposures cannot directly alter germline DNA sequence [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;As summary data from a vast range of genome-wide association studies (GWAS) have become widely and freely available, it has become possible to run every permutation of the vast number of exposure-outcome relationships that exist using MR methods. This, in principle, is a good thing. Although MR is not without its limitations (and critics), it is a potentially powerful tool that has provided important evidence—for example, suggesting a causal effect of cigarette smoking on some adverse mental health outcomes [&lt;span&gt;4&lt;/span&gt;]. However, with the advent of platforms such as MR Base (https://www.mrbase.org), all bivariate relationships tractable via MR using summary GWAS data can be considered to have been conducted [&lt;span&gt;5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Unfortunately, GWAS with ever-larger samples have enabled us to detect genetic variants associated with an exposure of interest that are &lt;i&gt;also&lt;/i&gt; associated with a range of other exposures (and not &lt;i&gt;via&lt;/i&gt; the exposure of interest), effectively reintroducing confounding when using MR. For example, genetic variants associated with smoking initiation are also associated with behavioural outcomes in young children, at an age before any exposure to smoking, suggesting that these variants may not be uniquely capturing smoking initiation, but instead some broad risk-taking phenotype [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In other words, while the exposure of interest may be smoking initiation, the primary phenotype most proximal to the genetic proxies used may be risk taking. This means that using these variants as a proxy for smoking initiation may introduce genetic confounding. Dynastic effects m","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 11","pages":"1861-1863"},"PeriodicalIF":5.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16627","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions","authors":"Paolo Mannelli","doi":"10.1111/add.16672","DOIUrl":"10.1111/add.16672","url":null,"abstract":"&lt;p&gt;D'Agata Mount et al. [&lt;span&gt;1&lt;/span&gt;] offer convincing proofs of the superiority of 32 mg/day buprenorphine for the low-threshold treatment of opioid use disorder (OUD), despite a non-randomized uncontrolled design. The study is a retrospective longitudinal observation and provides within group and between group comparisons with the 24 mg/day dose, identifying strong differences in a relatively small sample. This is undoubtedly fitting, the benchmark is now 32 mg, it was 24 mg before [&lt;span&gt;2&lt;/span&gt;] and 16 mg before that [&lt;span&gt;3&lt;/span&gt;]. Consistently, every round of evaluations has shown the use of higher doses to be associated with better outcomes and to be one of the best overdose prevention tools [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;One detail of the results stimulates reflection, which is concerning the increased influence of non-physiologic triggers of drug use when the buprenorphine dose is raised to 32 mg. Nothing in the results indicates it is a warning for the higher dose approach. In any case, using a wider range of buprenorphine doses may enhance the possibility to examine quantity and duration of treatment in relation to specific interventions, and further improve outcomes. To avoid a simplistic medication-centered approach, we could envision stepwise multi-phase protocols to address individual problems within a precision medicine framework that includes patients' genetic profile, lifestyle and environment, along with characteristics of disease and the proposed treatment [&lt;span&gt;5&lt;/span&gt;]. By now, we can identify triggers and match them with effective interventions. For example, the effects of psychosocial stressors can be partly reduced by adequate buprenorphine dosing [&lt;span&gt;6&lt;/span&gt;], but the administration of buprenorphine has limited efficacy on triggers of relapse tied to environmental stressors and social determinants of health, which require the development of sustainable long-term preventive community based interventions [&lt;span&gt;7&lt;/span&gt;]. National initiatives such as the National Institute of Health ‘Helping to End Addiction Long-term Initiative (HEAL)’ will provide a path to make evidence-based preventive services accessible to all persons who experience risk for substance use disorder and relapse [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;When it comes to the evaluation of triggers of drug use, a single measure of craving would be more powerful than the dichotomous values for each of the triggers in the study. Craving is an important patient-reported symptom, but finding consensus on evaluation methods remains a work in-progress [&lt;span&gt;9&lt;/span&gt;]. In this study, craving is listed as one of the physiologic withdrawal symptoms, instead of being considered a final expression of a diverse range of triggers [&lt;span&gt;10&lt;/span&gt;]. Following the latter interpretation, all physiologic and non-physiologic factors described in the study would be expressed through ratings of craving and drug seeking. How this can be done while preserving the individuality and traceab","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 11","pages":"1973-1974"},"PeriodicalIF":5.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16672","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early detection and prediction of non-fatal drug-related incidents and fatal overdose outbreaks using the Farrington algorithm.","authors":"Thomas Patton, Sharon Trillo-Park, Bethan Swift, Annick Bórquez","doi":"10.1111/add.16674","DOIUrl":"https://doi.org/10.1111/add.16674","url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study was to assess the validity of undertaking time-series analyses on both fatal and non-fatal drug overdose outcomes for the surveillance of emerging drug threats, and to determine the validity of analyzing non-fatal indicators to support the early detection of fatal overdose outbreaks.</p><p><strong>Design, setting and participants: </strong>Time-series analyses using county-level data containing fatal overdoses and non-fatal overdose counts were collected at monthly intervals between 2015 and 2021 in California and Florida, USA. To analyze these data, we used the Farrington algorithm (FA), a method used to detect aberrations in time-series data such that an abnormal increase in counts relative to previous observations would result in an alert. The FA's performance was compared with a bench-mark approach, using the standard deviation as an aberration detection threshold. We evaluated whether monthly alerts in non-fatal overdose can aid in identifying fatal drug overdose outbreaks, defined as a statistically significant increase in the 6-month overdose death rate. We also conducted analyses across regions, i.e. clusters of counties.</p><p><strong>Measurements: </strong>Measurements were taken during emergency department and emergency medical service visits.</p><p><strong>Findings: </strong>Both methods yielded a similar proportion of alerts across scenarios for non-fatal overdoses, while the bench-mark method yielded more alerts for fatal overdoses. For both methods, the correlations between surveillance evaluations were relatively poor in the detection of aberrations (typically < 35%) but were high between evaluations yielding no alerts (typically > 75%). For ongoing fatal overdose outbreaks, a strategy based on the detection of alerts at the county level from either method yielded a sensitivity of 66% for both California and Florida. At the regional level, the equivalent analyses had sensitivities of 81% for California and 77% for Florida.</p><p><strong>Conclusion: </strong>Aberration detection methods can support the early detection of fatal drug overdose outbreaks, particularly when methodologies are applied in combination rather than individual methods separately.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between state cannabis policies and cannabis use among adults and youth, United States, 2002-2019.","authors":"Seema Choksy Pessar, Rosanna Smart, Tim Naimi, Marlene Lira, Jason Blanchette, Anne Boustead, Rosalie Liccardo Pacula","doi":"10.1111/add.16663","DOIUrl":"https://doi.org/10.1111/add.16663","url":null,"abstract":"<p><strong>Aims: </strong>To measure the association between state cannabis policies and use among adults and youth in the United States from 2002 to 2019, given rapid policy liberalization and complex state cannabis policy environments.</p><p><strong>Design: </strong>Repeated cross-sectional time series analysis. Three sets of models assessed the linear association between the Cannabis Policy Scale (CPS), an aggregate measure of 17 state cannabis policy areas that weights each policy by its efficacy and implementation rating, and prevalence of cannabis use. The first included year and state fixed effects; the second added state-level controls; the third replaced state fixed effects with state random effects. Standard errors were clustered at the state level in all models.</p><p><strong>Setting and participants: </strong>United States.</p><p><strong>Measurements: </strong>Past-month prevalence of cannabis use is from the National Survey on Drug Use and Health Small Area Estimates, a nationally and state-representative cross-sectional survey of household population ages 12 and older for years 2002-2003 to 2018-2019. Exposure data include the CPS.</p><p><strong>Findings: </strong>A 10 percentage-point increase in the CPS (i.e. greater cannabis policy restrictiveness) was associated with lower past-month use prevalence by 0.81 (95% confidence interval [CI] = -1.05 to -0.56) to 0.97 (95% CI = -1.19 to -0.75) percentage-points for the population ages 12 years and older. When models were stratified by age, a 10 percentage-point increase in the CPS was associated with a 0.87 (95% CI = -1.13 to -0.61) to 1.04 percentage-point (95% CI = -1.03 to -0.84) reduction in past-month use prevalence for adults ages 18 years and older, and a 0.17 (95% CI = -0.24 to -0.09) to 0.21 percentage-point (95% CI = -0.35 to -0.07) reduction for youth ages 12-17 years.</p><p><strong>Conclusions: </strong>More restrictive US cannabis policies appear to be associated with reduced cannabis use for both adults and youth.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating gambling‐related suicide","authors":"Amanda Roberts, Jim Rogers, Elena Petrovskaya, Annie Ashton, Emily Beck, Charles Ritchie, Pauline Turnbull, Gursharan Johal, Richard James, Tony Parente, Chrissy Boyce, Samuel R. Chamberlain, Henrietta Bowden‐Jones, Paul Wong, Steve Sharman","doi":"10.1111/add.16668","DOIUrl":"https://doi.org/10.1111/add.16668","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":"2 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142251468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}